AbCellera Biologics Inc. ABCL Operating lease right-of-use asset amortization
Operating lease right-of-use asset amortization at other companies
Other financials
Where this comes from
Reported directly by AbCellera Biologics Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense.
The official record: AbCellera Biologics Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about AbCellera Biologics Inc.'s operating lease right-of-use asset amortization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is AbCellera Biologics Inc.'s operating lease right-of-use asset amortization?
- AbCellera Biologics Inc. (ABCL) reported operating lease right-of-use asset amortization of $1.82M in Q1 2026.
- How has AbCellera Biologics Inc.'s operating lease right-of-use asset amortization changed year-over-year?
- AbCellera Biologics Inc.'s operating lease right-of-use asset amortization increased by 42.6% year-over-year, from $1.27M to $1.82M.
- What is the long-term trend for AbCellera Biologics Inc.'s operating lease right-of-use asset amortization?
- Over 4 years (2021 to 2025), AbCellera Biologics Inc.'s operating lease right-of-use asset amortization has grown at a 24.3% compound annual growth rate (CAGR), from $2.79M to $6.65M.